Showing results (361-370 of 387) with videos related to
Sort By:
Pageof 39
American Journal of Hematology|January 3, 2022
Sustained, complete response to pexidartinib in a patient with CSF1R-mutated Erdheim-Chester diseaseJithma P Abeykoon, Terra L Lasho, Surendra Dasari, et al.JCO Oncology Practice|June 14, 2021
Outcomes of COVID-19 in Patients With Cancer: A Closer Look at Pre-Emptive Routine Screening StrategiesZhuoer Xie, Antoine N Saliba, Jithma Abeykoon, et al.Blood Cancer Journal|April 19, 2025
Risk of lymphoid malignancy associated with cancer predisposition genesNicholas J Boddicker, Raphael Mwangi, Dennis P Robinson, et al.Blood Advances|August 28, 2025
Cardiovascular Degeneration in Erdheim-Chester Disease: Prevalence, Burden, and OutcomesReema Kamal Tawfiq, Grant M Spears, Jason R Young, et al.Mayo Clinic Proceedings|April 2, 2013
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013Joseph R Mikhael, David Dingli, Vivek Roy, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2018
Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical TrialsMatthew J Maurer, Hervé Ghesquières, Brian K Link, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2015
Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With ImmunochemotherapyHervé Ghesquieres, Susan L Slager, Fabrice Jardin, et al.Blood Cancer Journal|June 20, 2024
Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCLKerstin Wenzl, Matthew E Stokes, Joseph P Novak, et al.American Journal of Hematology|April 28, 2021
Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemiaJithma P Abeykoon, Saurabh Zanwar, Stephen M Ansell, et al.Blood|January 28, 2021
Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repairJithma P Abeykoon, Xiaosheng Wu, Kevin E Nowakowski, et al.Pageof 39